INTRODUCTION
Hepatocellular carcinoma (HCC) is the second leading cause of malignancy related mortality all over the world with incidence rising both in the USA and abroad [1]. Globally, there are nearly 700,000 new cases of HCC reported each year. Studies show that the incidence rate continues to approximate the death rate indicating that most of the patients who develop HCC die from it. Fiveyear survival rates in the USA have modestly improved to approximately 26%. This improvement can be attributed to the advanced surveillance in identifiable high-risk groups (eg, patients of chronic infection with hepatitis B and C viruses) and to the improvement in surgical intervention (resection or transplantation) for patients with early stage disease [2].
According to the revised version of Barcelona Clinic for Liver Cancer (BCLC) system released by the American Association for the Study of Liver Diseases (AASLD) [3] , HCC is defined as very early when one nodule smaller than 2 cm is present in a cirrhotic liver Child-Pugh class A with no symptoms and no change in the performance status. Early HCC is defined when one nodule smaller than 5 cm or up to 3 nodules smaller than 3 cm each is/are present in a cirrhotic liver Child-Pugh class A or B with no symptoms and no change in the performance status.
HCC incidence is increasing in Egypt. In the present study, we aimed at investigating the diagnostic utility of serum MDK evaluation as a biomarker for very early and early HCC and especially for AFP negative cases.
PATIENTS AND METHODS
This is a case-control study that included 46 patients diagnosed with HCC (37 males and 9 females with age in the range of 45-88 years) as the case group and 46 cirrhotic patients (34 males and 12 females with age in the range of 45-80 years) as the disease control group. All these patients were admitted to Tropical Medicine Department affiliated to Zagazig university hospitals in the period from June, 2016 to February, 2017.
Also, 46 healthy subjects selected from patients' relatives (32 males and 14 females with age in the range of 44-87 years) were included and represented the healthy control group.
All study participants exhibited good compliance and provided a written consent to be included.
Patients with HCC and naïve to treatment (diagnosed by triphasic CT criteria and / or by histopathology according to AASLD guidelines) were included in group (A). Cirrhotic patients with no evidence of hepatic focal mass(es) in ultrasound evaluation were included in group (B). Diagnosis of liver cirrhosis was based on clinical, laboratory and imaging studies. All patients included in groups A and B were ChildPugh class A. Healthy controls included in group (C) were selected from patients' relatives and were free from any clinical, laboratory and sonographic abnormalities.
Patients who had any malignancy other than HCC, those who had a history of intravenous administration of heparin prior to evaluation of their serum midkine by 48 hours, those who had rheumatoid arthritis, Child-Pugh classes B and C cirrhotic patients and those having end stage major organ disease were excluded from the study.
All participants were subjected to history taking, thorough clinical examination and laboratory investigations in the form of complete blood count, liver function tests, kidney function tests, coagulation profile, viral markers (HCV Ab and HBsAg) and alpha fetoprotein assessment. These investigations were done by the conventional methods used.
Midkine assessment was done for all participants. The assay was performed using enzyme-linked immunosorbent assay (ELISA) kits supplied by Glory Science (Glory Science Co., Ltd, 2400 Veterans Blvd. Suite 16-101, Del Rio, TX 78840, USA).
Imaging studies were performed for all patients. Pelviabdominal ultrasonography using sonoscape c11 was done. The liver was examined for its size, surface, echogenicity and hepatic viens. The portal vein diameter and splenic axis were measured. A special emphasis regarding the HCC masses was done including their number, site, size, echogenicity and any special character. ). Validity of a screening test was expressed as sensitivity, specificity, positive predictive value, negative predictive value and accuracy. For all these statistical tests used, the threshold of significance was fixed at 5% level (P-value). The smaller the P-value obtained, the more significant were the results. The aim of this study was to assess the role of serum midkine measurement as a non-invasive biomarker for diagnosis of very early, early and AFP negative HCC.
RESULTS
The present study was conducted on 138 subjects divided into 3 groups; 46 patients with HCC as group A, 46 cirrhotic patients as group B and 46 apparently healthy control subjects as group C. All patients were matched as regard age, gender and residence. Child Pugh class A patients were included in the study while Child Pugh classes B and C were excluded. Patients with HCC were of very early and early stages of the disease. Advanced stage of HCC and cases with portal vein thrombosis were excluded from the study.
Our results revealed a significantly higher level of AFP in HCC group (median =91 ng/mL) and chronic liver disease group (median= 16.4 ng/mL) compared to the control group (median= 1.9 ng/mL). In addition, AFP values were significantly higher in HCC patients compared to chronic liver disease patients. This was in agreement with Wei et al. [20] and Othman et al.
[21] who found that AFP increases in chronic liver disease patients and also proved that AFP increases significantly in HCC patients than in chronic liver disease patients.
In this study, there was a highly significant statistical difference between the mean value of serum MDK levels in patients with HCC compared to patients with liver cirrhosis and the healthy controls with mean ± SD values of 62.6 ± 26, 25.8± 9.9 and 19.1 ±4.2 ng/dL respectively (p<0.001). These findings are in agreement with those of Zhu et al. [22] who found that serum MDK was significantly elevated among HCC patients when compared with chronic liver disease patients and healthy individuals.
In the present study, MDK had sensitivity of 91% and specificity of 90% for detection of HCC at the optimal cut off value of 34 ng/dL with AUC of 0.94 when compared with liver cirrhosis while AFP had sensitivity of 56% and specificity of 90% at the optimal cut off value of 21.5 ng/mL with AUC of 0.63 when compared with liver cirrhosis. These results are similar to those of Karim et al. [23] who found that MDK and AFP had sensitivities of (92.5% versus 40%), specificities of (83.3% versus 96.7%) respectively. Through the analysis of the ROC curve, they found that the AUC (0.941) for serum MDK was larger than that of serum AFP (0.671).
On the contrary of the previous results, Hung et al. [24] found that at cut off value of 50 ng/dL, MDK had sensitivity of 51% and specificity of 60%. This difference in results can be attributed to difference in the studied population and the number of patients included in both studies. Patients included in that study had HCC complicating HBV induced liver cirrhosis and were of advanced stage of HCC while most of the patients in this study were HCC complicating HCV induced liver cirrhosis and all of them were of very early and early stages of the disease.
The best cutoff values for MDK and AFP to discriminate very early HCC ≤2 cm from nonhepatocellular carcinoma controls (liver cirrhosis patients and healthy controls) were 32 ng/dL and 18.5ng/mL respectively; with sensitivities of 94% versus 70% and specificities of 91.3% versus 86%. The AUC was 0.8 for serum MDK and was found to be larger than that of serum AFP (0.7) with a highly significant statistical difference (P<0.001). While the best cutoff values for MDK and AFP to discriminate early HCC 2-5 cm in diameter from non-hepatocellular carcinoma controls (liver cirrhosis patients and the healthy controls) were 27.5 ng/dL and 19.5 ng/mL respectively; with sensitivities of 96% versus 50% and specificities of 82.6% versus 80%. The AUC was 0.9 for MDK and was found to be much larger than that of AFP (0.6) with highly significant statistical difference (P <0.001). This means that the overall diagnostic performance of serum MDK for diagnosis of very early HCC ≤2 cm and early HCC 2-5cm in diameter is much better than that of serum AFP. This is in agreement with Zhu et al. [22] who reported that serum MDK had a better performance compared with AFP for distinguishing very early hepatocellular carcinoma as well as early hepatocellular carcinoma from liver cirrhosis and healthy controls.
In this study, there was highly significant statistical difference between mean value of serum MDK in HCC patients negative for AFP (values < 20 ng/mL) compared to HCC patients positive for AFP (values >20 ng/mL) with mean ± SD values of 46 ± 10.9 and 75± 28 ng/dL respectively (p<0.001). Diagnostic performance of serum MDK in discriminating HCC negative for AFP from liver cirrhosis and healthy controls revealed that serum MDK at a cut off value of 36.5 ng/dL showed sensitivity of 85%, specificity of 88%, PPV of 77%, NPV of 92% and AUC of 0.934 (p<0.001). These results agree with results obtained by Zhu et al. [16] who reported that serum MDK had a good performance for distinguishing AFP-negative hepatocellular carcinomas from non-hepatocellular carcinoma controls with AUC 0.926.
Finally, this study revealed that assessment of serum MDK is to be used as a non-invasive marker for detection of HCC patients complicating chronic hepatitis C with very early and early disease stages and/or negative for AFP.
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